Back to Top
CITATIONS
Latest Publications Featuring ichorbio Products
Loading...
Your Partner in Development
From early-stage research through preclinical development, ichorbio provides the tools and support you need to advance your pipeline. Our commitment to quality, comprehensive documentation, and reliable bulk supply helps accelerate your journey from innovative concept to breakthrough therapy.
-
Posted: August 15, 2025Categories: ichorbio Citations (Resources)
Read more »Humoral Immunity's Unexpected Role in Checkpoint Immunotherapy
A recent article published in Nature (Vol. 631, 23 July 2025) reveals that antibody-mediated humoral immunity, specifically the presence of autoantibodies (AAbs), can significantly influence the effectiveness of checkpoint immunotherapy (CPI) for cancer. The study, which used a high-throughput...
-
Posted: August 07, 2025Categories: Antibodies in Clinic / Clinical Trials
Read more »FDA Approval Spotlight: Linvoseltamab — A BCMA x CD3 Bispecific for Multiple Myeloma
In July 2025, the FDA granted accelerated approval to linvoseltamab, a BCMA × CD3 T-cell engaging bispecific antibody, for the treatment of ...
-
Posted: July 28, 2025Categories: ichorbio Citations (Resources)
Read more »Oncolytic Virus Expressing Non-Secreted DR-18 Cytokine Induces Potent, Systemic Antitumor Immunity
A recent study published in
Molecular Therapy: Oncology (Vol. 33, Sept 2025) demonstrates the therapeutic potential of a novel oncolytic vaccinia...
